News

15.04.21 Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021
25.03.21 Medannex sweeps the board at Scotland’s Life Sciences Annual Awards
05.01.21 Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace
16.12.20 Medannex chosen by Welp Magazine as a company to watch in the UK Clinical Trials space
17.08.20 Medannex completes final tranche of £11m Series B investment, led by Morningside Venture Capital
22.06.20 Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
  1. 1
  2. 2
  3. 3
  4. 4